ESTRO 2024 - Abstract Book

S1529

Clinical - Lower GI

ESTRO 2024

Conclusion:

Neoadjuvant chemoradiotherapy with dose intensification in Locally Advanced Rectal Cancer patients resulted in favorable long-term oncological outcomes especially with a high pCR rate, an optimal impact of Mandard Tumor Regression Grade on LC and OS and with an acceptable toxicity.

Keywords: Clinical outcomes, Rectal cancer

1832

Digital Poster

Total Neoadjuvant Therapy protocol for locally advanced rectal cancer

Leire Romo Tapias, Idoya Reta Decoreau, Angel Rodriguez Sanchez, Celia Fernandez Trueba, Jose Antonio Arresti Sanchez, Karla Berenice Urquilla Ventura, Lucia Flores Barrenechea, Maite Ispizua Ojanguren, Maria Madrid Nebreda, Marta Labado Mora, Marta Carranza Pose, Marta Isabel Gnecchi XX, Miguel Antonio Arguello Garcia, Oriana Briz Leon, Victor Manuel Barrondo Azcorra, Maider Sierra Marin, Francisco Javier Fuertes Velez

Basurto University Hospital, Radiation Oncology, Bilbao, Spain

Purpose/Objective:

Current standard treatment for locally advanced rectal cancer is preoperative chemoradiotherapy followed by postoperative adjuvant chemotherapy. Nevertheless, multiple studies propose Total Neoadjuvant Therapy (TNT), which aims to deliver a short-course of radiotherapy plus neoadjuvant chemotherapy prior to surgery (or even avoiding it), endorsing satisfactory oncological results. The aim of this study is to demonstrate that this treatment can be considered a new standard of care by analyzing the TNT protocol outcomes of our center.

Material/Methods: